The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review.

ABSTRACT:

Background and objective

The survival benefit of induction therapy for non-small cell lung cancer (NSCLC) remains controversial. Recently, the outcomes of systemic therapy for NSCLC have dramatically changed with the advent of molecular target drugs and immune checkpoint inhibitors (ICIs). The present review was conducted to investigate the outcomes of induction therapy with reference to randomized control trials (RCTs).

Methods

We reviewed RCTs and ongoing clinical trials between 1990 and 2022 using relevant databases: PubMed, Web of Science, and EMBASE database. We investigated the outcomes of induction therapy.

Key content and findings

Induction therapy was associated with longer overall survival in comparison to surgery alone in several RCTs for stage III disease.

SUBMITTER: Shinohara S 

PROVIDER: S-EPMC9992625 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature